Adverse effect of increased left ventricular wall thickness on five year outcomes of patients with negative

Thomas F Walsh1, Erica Dall'Armellina, Haroon Chughtai

  • 1Department of Internal Medicine (Cardiology Section), Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, USA. Thomas.Walsh@jax.ufl.edu

Insights

Increased left ventricular end-diastolic wall thickness (EDWT) is a cardiac risk factor in patients without dobutamine-induced wall motion abnormalities (WMA). This finding highlights EDWT as a key indicator for cardiac events.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging

Background:

  • Assessing cardiac prognosis in patients without inducible ischemia but with increased left ventricular end-diastolic wall thickness (EDWT).
  • Evaluating the prognostic significance of EDWT in the absence of dobutamine-induced left ventricular wall motion abnormalities (WMA).

Purpose of the Study:

  • To determine if increased LV EDWT, without dobutamine-induced WMA, predicts cardiac events.
  • To identify novel risk factors for adverse cardiac outcomes in specific patient populations.

Main Methods:

  • 175 patients underwent dobutamine stress cardiovascular magnetic resonance (DCMR) with gradient-echo cines (1999-2001).
  • Patients had preserved LV ejection fraction (>55%) and no inducible WMA.
  • Cardiac events (death, MI, USA, CHF) were tracked for an average of 5.5 years post-DCMR.

Main Results:

  • A LV EDWT ≥12 mm independently predicted increased cardiac death and myocardial infarction (MI) (HR 6.0, p=0.0016).
  • Increased LV EDWT also predicted a composite endpoint of MI, cardiac death, and hospitalization for unstable angina (USA) or congestive heart failure (CHF) (HR 3.0, p=0.0005).
  • Multivariate analysis adjusted for Framingham risk factors confirmed these associations.

Conclusions:

  • Cardiovascular magnetic resonance (CMR) measures of increased LV wall thickness are a risk factor for cardiac events, even with negative dobutamine stress tests for ischemia.
  • LV wall thickness should be considered in risk stratification for patients undergoing dobutamine stress imaging.
  • Further research on LV wall thickness and mass using steady-state free precession techniques is recommended.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...